<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046550</url>
  </required_header>
  <id_info>
    <org_study_id>NTM-1634-001</org_study_id>
    <secondary_id>272201600009C-2-0-1</secondary_id>
    <nct_id>NCT03046550</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults</brief_title>
  <official_title>A Phase I, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and pharmacokinetics of NTM-1634 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies.&#xD;
&#xD;
      This study is a randomized, double-blind, placebo controlled dose escalation study of three&#xD;
      dose cohorts. Cohort A: 0.33mg/kg; B: 0.66mg/kg; and C: 1 mg/kg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of Serious Adverse Events following administration of NTM-1634 to the final follow-up visit</measure>
    <time_frame>121 days</time_frame>
    <description>number of SAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of Adverse Events from administration of NTM-1634 to Day 57</measure>
    <time_frame>57 days</time_frame>
    <description>number of AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of changes from baseline in physical examination following administration of NTM-1634 to the final follow-up visit</measure>
    <time_frame>121 days</time_frame>
    <description>types of changes of physical exam findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of changes from baseline in vital signs following administration of NTM-1634 to the final follow-up visit</measure>
    <time_frame>121 day</time_frame>
    <description>change in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of changes from baseline in clinical safety laboratory values following administration of NTM-1634 to the final follow-up visit</measure>
    <time_frame>121 day</time_frame>
    <description>change in lab values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of changes from baseline in ECG parameters post administration of NTM-1634 on Day 1 (day of infusion)</measure>
    <time_frame>1 day</time_frame>
    <description>changes in ECG parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The assessment of Cmax for each of the four monoclonal antibodies of NTM-1634</measure>
    <time_frame>121 days</time_frame>
    <description>Cmax assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of Tmax for each of the four monoclonal antibodies of NTM-1634</measure>
    <time_frame>121 days</time_frame>
    <description>Tmax assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of AUC(0-t) for each of the four monoclonal antibodies of NTM-1634</measure>
    <time_frame>121 days</time_frame>
    <description>AUC(0-t) assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of human anti-human antibodies (HAHA) via blood collection at Days 1, 29, 57, 91 and 121.</measure>
    <time_frame>Days 1, 29, 57, 91, and 121</time_frame>
    <description>antibody development</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTM-1634</intervention_name>
    <description>NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent understood and signed&#xD;
&#xD;
          2. Healthy male or healthy, non-pregnant, non-lactating female&#xD;
&#xD;
          3. Willingness to comply and be available for all protocol procedures including inpatient&#xD;
             confinement for 36 - 48 hours&#xD;
&#xD;
          4. Age between 18 and 45 years, inclusive on the day of infusion&#xD;
&#xD;
          5. Body Mass Index (BMI) of ≥18.5 and ≤30 kg/m2&#xD;
&#xD;
          6. If the subject is female and of childbearing potential, she has a negative urine&#xD;
             pregnancy test at screening and negative serum test within 24 hours prior to infusion&#xD;
&#xD;
               -  Note: A woman is considered of childbearing potential unless post-menopausal (≥ 1&#xD;
                  year without menses) or surgically sterilized via bilateral oophorectomy, or&#xD;
                  hysterectomy or bilateral tubal ligation or successful Essure placement with&#xD;
                  documented confirmation test at least 3 months after the procedure.&#xD;
&#xD;
          7. If the subject is female and of childbearing potential, she agrees to practice&#xD;
             abstinence from sexual intercourse with men or use acceptable contraception up to&#xD;
             visit 12 of the study&#xD;
&#xD;
               -  Note: Acceptable contraception methods are restricted to effective devices&#xD;
                  (Intrauterine Contraceptive Devices , NuvaRing®)&#xD;
&#xD;
          8. The hemoglobin, platelet count, white blood cell count and absolute neutrophil count&#xD;
             are within normal limits&#xD;
&#xD;
          9. The urine dipstick results on protein, glucose and blood are negative or trace&#xD;
&#xD;
               -  Note: Menstruating females failing inclusion criteria due to a positive blood on&#xD;
                  urine dipstick may be retested following cessation of menses.&#xD;
&#xD;
         10. Chemistry screening laboratory tests as outlined in Section 7.5.1.4 are in the normal&#xD;
             reference range&#xD;
&#xD;
               -  Note: The following exceptions to laboratory normal reference ranges are allowed:&#xD;
                  Creatinine, Blood Urea Nitrogen (BUN), total bilirubin, AST, ALT, lipase,&#xD;
                  amylase, Prothrombin Time (PT), Partial Thromboplastin Time (PTT) below the lower&#xD;
                  limit of normal (LLN); CK less than 400mg/ml; Glucose, potassium, total protein,&#xD;
                  and alkaline phosphatase with a toxicity grade of 1 is allowable; albumin above&#xD;
                  the upper limit of normal (ULN).&#xD;
&#xD;
               -  Laboratory values that are outside the range of eligibility but are thought to be&#xD;
                  due to an acute condition or due to laboratory error may be repeated once.&#xD;
&#xD;
               -  Abnormalities in mean corpuscular volume (MCV), mean corpuscular hemoglobin&#xD;
                  (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution&#xD;
                  width (RDW), mean platelet volume (MPV), and nucleated red blood cell count (NRBC&#xD;
                  CT), which are included in a complete blood count with differential, will not be&#xD;
                  exclusions.&#xD;
&#xD;
         11. Has adequate venous access for the infusion&#xD;
&#xD;
         12. The urine drug screen is negative&#xD;
&#xD;
         13. Breathalyzer test is negative&#xD;
&#xD;
         14. Available for follow-up for the duration of the study&#xD;
&#xD;
         15. Agrees not to participate in vigorous activity 72 hours prior to dosing through day 15&#xD;
             post dosing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of a chronic medical condition that would either interfere with the accurate&#xD;
             assessment of the objectives of the study or increase the risk profile of the subject.&#xD;
&#xD;
               -  Note: Chronic medical conditions include diabetes; Asthma requiring use of&#xD;
                  medication in the year before screening; Autoimmune disorder such as lupus,&#xD;
                  Wegener's, rheumatoid arthritis, thyroid disease; Coronary artery disease;&#xD;
                  Chronic hypertension; History of malignancy except low-grade (squamous and basal&#xD;
                  cell) skin cancer thought to be cured; chronic renal, hepatic, pulmonary, or&#xD;
                  endocrine disease (except previous asthma which has required no treatment for the&#xD;
                  past year);&#xD;
&#xD;
          2. History of severe allergic reaction of any type to medications, bee stings, food, or&#xD;
             environmental factors or hypersensitivity or reaction to immunoglobulins.&#xD;
&#xD;
               -  Note: Severe allergic reaction is defined as any of the following: anaphylaxis,&#xD;
                  urticaria, or angioedema&#xD;
&#xD;
          3. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTc interval &gt;450 milliseconds)&#xD;
&#xD;
          4. Clinically significant abnormal electrocardiogram at screening.&#xD;
&#xD;
               -  Note: Clinically significant abnormal ECG results include: complete left or right&#xD;
                  bundle branch block; other ventricular conduction block; 2nd degree or 3rd degree&#xD;
                  atrioventricular (AV) block; sustained ventricular arrhythmia; sustained atrial&#xD;
                  arrhythmia; two Premature Ventricular Contractions in a row; pattern of ST&#xD;
                  elevation felt consistent with cardiac ischemia; or any condition deemed&#xD;
                  clinically significant by a study investigator&#xD;
&#xD;
          5. Positive serology results for HIV, HBsAg, or HCV antibodies&#xD;
&#xD;
          6. Febrile illness with temperature ≥38°C within 7 days of dosing&#xD;
&#xD;
          7. Pregnant or breastfeeding&#xD;
&#xD;
          8. Donated blood within 56 days of enrollment&#xD;
&#xD;
          9. Known allergic reactions to any of the study product components present in the&#xD;
             formulation or in the processing, as listed in the Investigator Brochure&#xD;
&#xD;
         10. Treatment with another investigational drug within 28 days of dosing&#xD;
&#xD;
         11. Treatment with a monoclonal antibody at any time&#xD;
&#xD;
         12. Receipt of antibody (e.g. TIG, VZIG, IVIG, IM gamma globulin) or blood transfusion&#xD;
             within 6 months or within 5 half-lives of the specific product given&#xD;
&#xD;
         13. Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements&#xD;
&#xD;
         14. Use of H1 antihistamines or beta-blockers within 5 days of dosing&#xD;
&#xD;
         15. Use of any prohibited medication within 28 days prior to study entry or planned use&#xD;
             during the study period&#xD;
&#xD;
               -  Note: Prohibited medications include immunosuppressives (except Nonsteroidal&#xD;
                  Anti-Inflammatory Drugs [NSAIDS]); immune modulators; oral corticosteroids&#xD;
                  (topical/intranasal steroids are acceptable); anti-neoplastic agents; any vaccine&#xD;
                  (licensed or investigational)&#xD;
&#xD;
         16. Previous exposure to botulinum toxin, receipt of antibodies against botulinum toxin,&#xD;
             or previous treatment with equine antitoxin&#xD;
&#xD;
         17. Any previous injection or planned injection within 4 months after enrollment of&#xD;
             botulinum toxin for cosmetic reasons, spastic dysphonia, torticollis, or any other&#xD;
             reason&#xD;
&#xD;
         18. Any specific condition that in the judgment of the investigator precludes&#xD;
             participation because it could affect subject safety&#xD;
&#xD;
         19. Plans to enroll or is already enrolled in another clinical trial* that could interfere&#xD;
             with safety assessment of the investigational product at any time during the study&#xD;
             period&#xD;
&#xD;
               -  Note: Includes trials that have a study intervention such as a drug, biologic, or&#xD;
                  device&#xD;
&#xD;
         20. Is a study site employee or staff&#xD;
&#xD;
               -  Note: Site employees or staff include the PIs and sub-investigators or staff who&#xD;
                  are supervised by the PI or Sub-Investigators&#xD;
&#xD;
         21. Systolic blood pressure &gt;140mm Hg or diastolic blood pressure &gt;90 mm Hg&#xD;
&#xD;
         22. Resting hear rate &lt;50 or &gt;100 beats per minute&#xD;
&#xD;
         23. Oral temperature ≥ 38°C (100.4°F)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Ruff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Early Phase Services, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

